FILTER
FILTERED INTERVIEW RESULTS
Milton Boyer and David Stevens
CEO (MB) & CCO (DS), KINDEVA DRUG DELIVERY
"A shift in pharma’s pipeline catalyzes a need for changes to CDMOs’ capacity."
Paolo Paissoni
DIRECTOR OF INNOVATION AND BUSINESS DEVELOPMENT, PROCOS SPA
"We are currently building a new workshop in which we are specifically going to add small-scale lines to support clinical trial supply and generic product manufacturing."
Louis P. Kassa III
PRESIDENT AND CEO, PENNSYLVANIA BIOTECHNOLOGY CENTER (PABC)
"We want scientists to focus on science, and we offer them the equipment and services so they can do that."
Debbie Hart
PRESIDENT, BIONJ
"We used our voice to educate on the value of medical innovation and boasted the strength of New Jersey’s vibrant ecosystem, which was responsible for more than 50% of all novel FDA approvals in 2023."
Ajay Tandon
CEO, VEEDA CLINICAL RESEARCH LIMITED
"Although the US may have been ahead in technology adoption initially, India has been catching up rapidly."
Kimberly Young
NORTH AMERICA HEAD OF LIFE SCIENCES, CITI COMMERCIAL BANK
"Therapeutic areas that appeal to investors, strong management teams, relationships with large pharma, and the ability to generate data and advance pipelines are key to attracting funding."
Donna LaVoie
PRESIDENT AND CEO, LAVOIE HEALTH SCIENCE
"There is an insatiable demand for capital and there is too much innovation to fund."
Arda Ural
PARTNER & AMERICAS INDUSTRY MARKET LEADER, HEALTH SCIENCES AND WELLNESS, EY
"The biotech sector has room to grow. Oncology, blood disorders, immunology, inflammation, rare diseases, and neurology are key therapeutic areas attracting capital and fostering innovation."
Gil Roth
PRESIDENT, PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION (PBOA)
"There are signs of funding returning in the first half of this year, potentially revitalizing early-stage projects, and benefiting the CDMO sector."
Hernan Bazan
CEO AND CO-FOUNDER, SOUTH RAMPART PHARMA
“The best way to attract investment is with serious science and well-validated clinical mechanisms of action. An asset in the clinic with a well-described mechanism of action for how it works and peer-reviewed science, including NIH funding, helps with the validity.”
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
Latin America Petrochemicals and Chemicals 2024 - Digital Interactive
The Latin America Petrochemicals and Chemicals 2024 report, produced in alliance with APLA, explores the current state of these industries, the challenges they face, and the opportunities they offer.
The Latin America Petrochemicals and Chemicals 2024 report, produced in alliance with APLA, explores the current state of these industries, the challenges they face, and the opportunities they offer.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
